Into a Post-COVID World: Overcoming Pharmaceutical Supply Chain Challenges and Unlocking CDMO Opportunities

The global market for pharmaceutical contract development and manufacturing organizations (CDMOs) had a strong start in 2022, when it was valued at $90 billion.

This momentum is set to continue, largely as a result of a global rise in chronic diseases and pandemic-induced capacity challenges which have led to a heightened reliance on the capabilities of CDMOs.

In an industry that is ever-evolving, trends and opportunities unfold at every turn. Our Global Business Development Lead Tom Wilson recently spoke with CPhI Online to share his insights on recent supply chain challenges and discuss the opportunities in the CDMO space.

Continuing collaboration with CDMOs

Before COVID-19, CDMOs operated as competitors, working to win more business and become the ‘go-to’ organizations for their partners. But this changed when the pandemic hit, opening up new opportunities for CDMOs to do something new - collaborate with each other.

CDMOs partnered with pharma companies and other CDMOs to bring their best scientists together in an effort to solve a global problem that had never been seen before.

As a result, CDMOs have found that by working together rather than against each other, they have found more creative and impactful ways to overcome enormous challenges. By combining their shared expertise and resources, they have succeeded in delivering medicines to patients faster than ever before.

As we move into a post-COVID landscape, it is likely that this momentum will continue, as evidenced by recent interactions across trade events such as CPhI.

These events have seen CDMOs continuing to seek out one another for projects that help them with their most pressing objectives - getting their medicines to patients.

Preparing for upcoming supply chain challenges

The industry has been plagued by supply chain disruptions over the last two years, and capacity constraints for pharmaceutical development are expected to continue for a number of reasons.

One of which includes the high number of new drug products to treat COVID-19 receiving fast approval that remain in demand. Additionally, drugs in clinical trials were delayed when the pandemic hit which are now being picked up again. As a result, there’s a high level of built-up demand that, combined with current talent shortages in the market, significantly impacts various partners across the supply chain.

Another current issue that is certain to impact global supply chains is the current situation in Ukraine. Ukraine has an abundance of nickel mines, and it's likely that we will soon experience challenges when it comes to stainless steel supplies.

What makes Pfizer CentreOne altogether different when it comes to overcoming these challenges?

What sets Pfizer CentreOne apart from many other CDMOs is the fact that we’re a part of a brand synonymous with success - Pfizer. Our goal is to make the science, capabilities, and people of Pfizer available to our partners to help us on our joint mission to bring life-changing medicines to patients.

Pfizer CentreOne is also backed by a culture of confidentiality that ensures our commitment to protecting the pharmaceutical IP of our partners. This is built on processes and robust agnostic systems to ensure that the patient always remains the priority while keeping our partners’ secrets safe.

Overall, we serve as an access point for the world-class expertise and capabilities of the wider Pfizer network. We help our partners navigate the entire suite of services to get them what they need, when they need it.

Find out more about what makes Pfizer CentreOne an altogether different kind of CDMO.